RespireRx Pharmaceuticals Inc. With a strong commitment to innovation and scientific research, RespireRx offers a range of innovative products and services aimed at combating various medical conditions. One of their key platforms is the Neurotransmission platform, which focuses on developing pharmaceutical cannabinoids for the treatment of obstructive sleep apnea.

With their flagship product, Dronabinol, RespireRx aims to provide effective solutions for patients suffering from this debilitating condition. They are actively involved in the regulatory process to ensure the availability and accessibility of these life-changing treatments. In addition, RespireRx is engaged in the development of neuromodulators and ampakines.

Their ampakine platform targets conditions such as attention deficit hyperactivity disorder (ADHD) and spinal cord injury (SCI), while their GABAkines platform focuses on epilepsy and pain management. RespireRx is driven by a robust product pipeline and actively collaborates with leading institutions like University College London for research collaborations. They are dedicated to improving the lives of patients worldwide by revolutionizing the field of neuropharmacology.

Contact RespireRx Pharmaceuticals Inc